1. Product Description
Orsin Medical Technology’s Cell-Free DNA (cfDNA) Collection and Preservation System offers a reliable, non-invasive solution for the efficient stabilization and transport of high-quality cfDNA samples. Designed for clinical research, liquid biopsy, and molecular diagnostics, our proprietary technology ensures the integrity of cfDNA from blood samples, minimizing degradation and contamination.
Key Features:
✔ Room-Temperature Stability – Eliminates the need for cold chain transport, reducing costs and logistical challenges.
✔ High Yield & Purity – Preserves cfDNA fragments for accurate downstream analysis (NGS, PCR, etc.).
✔ Clinically Validated – Optimized for compatibility with major diagnostic platforms.
✔ User-Friendly – Simple blood collection and seamless integration into lab workflows.
Ideal for cancer screening, prenatal testing, and disease monitoring, Orsin’s cfDNA system empowers precision medicine with robust, reproducible results.
2. Specification
Parameter | Description/Options |
---|---|
Tube Cap Color | Red, Lavender (Purple), Green, Gray, Blue, Yellow, Black, etc. |
Additive Type | None (Clot activator), EDTA, Heparin, Sodium Citrate, Sodium Fluoride, etc. |
Clinical Use | Serum separation, Hematology, Coagulation, Chemistry, Glucose, Blood Bank, etc. |
Nominal Volume | 2ml, 3ml, 4ml, 5ml, 6ml, 7ml, 8ml, 10ml, etc. |
Draw Volume Range | ±10% of nominal volume (e.g., 4.5-5.5ml for 5ml tube) |
Tube Diameter | 13mm, 16mm (standard adult size) |
Tube Length | 75mm, 100mm, etc. |
Material | PET plastic, Glass |
Sterilization | Gamma irradiation, EO Gas |
Expiry Period | Typically 12-36 months (from date of manufacture) |
Hemolysis Rate | ≤0.1% (for most chemistry tubes) |
Clotting Time | 30 mins (for serum tubes with clot activator) |
Centrifuge Speed | 1300-2200g (tube material dependent) |
Safety Features | Hemogard™ closure, BD-PTS, Needle protection system |
Certifications | ISO 6710, CE Marked, FDA 510(k) |
Common Parameters by Tube Color (Example):
Cap Color | Additive | Mixing | Inversion Count | Clinical Applications |
---|---|---|---|---|
Red | None/Clot activator | 5× | 5-6 | Serum chemistry, Immunology |
Lavender | K2/K3 EDTA | 8-10× | 8-10 | Hematology (CBC, Blood Smear) |
Green | Lithium Heparin | 8-10× | 8-10 | Plasma chemistry, STAT tests |
Gray | NaF/K Oxalate | 8-10× | 8-10 | Glucose tolerance, Alcohol tests |
Blue | Sodium Citrate | 3-4× | 3-4 | Coagulation tests (PT, APTT) |
3 . Application
Early Cancer Detection – Isolate tumor-derived cfDNA (ctDNA) for multi-cancer screening (e.g., lung, breast, colorectal).
Minimal Residual Disease (MRD) Monitoring – Track recurrence post-surgery/chemotherapy with high sensitivity.
Therapy Selection & Resistance – Profile mutations (e.g., EGFR, KRAS) to guide targeted therapies.
Liquid Biopsy – Alternative to invasive tissue biopsies for metastatic or hard-to-access tumors.
Compatible Tests: NGS panels, ddPCR, methylation profiling.
Non-Invasive Prenatal Testing (NIPT) – Detect fetal chromosomal abnormalities (e.g., trisomy 21, 18, 13) from maternal blood.
Preimplantation Genetic Testing (PGT) – Support IVF embryo screening.
Preeclampsia Risk Assessment – Analyze placental cfDNA for early预警.
Organ Rejection Monitoring – Detect donor-derived cfDNA (dd-cfDNA) in transplant recipients (e.g., kidney, heart, liver).
Graft-versus-Host Disease (GVHD) – Monitor post-hematopoietic stem cell transplantation (HSCT).
Pathogen Detection – Identify microbial cfDNA in sepsis or occult infections (e.g., TB, CMV).
Autoimmune Disease Research – Study cfDNA release patterns in lupus, rheumatoid arthritis, etc.
Neurodegenerative Disorders – Investigate cfDNA biomarkers for Alzheimer’s, Parkinson’s.
Cardiovascular Risk – Correlate cfDNA levels with myocardial injury or stroke.
Biomarker Discovery – Explore novel cfDNA signatures for diagnostics/therapeutics.
Clinical Trials – Standardize sample collection for multicenter studies.
Pathogen Detection – Identify microbial cfDNA in sepsis or occult infections (e.g., TB, CMV).
Autoimmune Disease Research – Study cfDNA release patterns in lupus, rheumatoid arthritis, etc.
Neurodegenerative Disorders – Investigate cfDNA biomarkers for Alzheimer’s, Parkinson’s.
Cardiovascular Risk – Correlate cfDNA levels with myocardial injury or stroke.
Biomarker Discovery – Explore novel cfDNA signatures for diagnostics/therapeutics.
Clinical Trials – Standardize sample collection for multicenter studies.